Advertisement

Document › Details
Novo Holdings A/S. (6/23/17). "Press Release: Novo A/S Renamed Novo Holdings A/S".
![]() |
Organisation | Novo A/S |
Today | Novo Holdings A/S | |
Group | Novo Group (Group) | |
Organisation 2 | Novo Holdings A/S | |
Group | Novo Group (Group) | |
![]() |
Product | venture capital |
Product 2 | LIFE SCIENCES | |
![]() |
Person | Mostrup Scheel, Christian (Novo Group 201706 Senior Press OFficer of Novo Holdings A/S) |
Novo A/S, the holding company for the companies in the Novo Group, is changing its name to Novo Holdings A/S.
The new name will more accurately reflect the company’s role and will help to reduce any confusion with the other companies in the Novo Group.
In connection with the new name, Novo Holdings will add the tagline “Investors in life science”. This clarifies that the company is a life-science focused investor, in addition to being the holding company of the Novo Group.
Novo Holdings currently wholly or partly owns more than 80 life-science companies, many of which are headquartered in the United States. Last year, the company invested DKK 8.7 billion in the life sciences. The strategy of Novo Holdings is to substantially increase its investments in life-science companies over the coming years.
Kasim Kutay, CEO of Novo Holdings, says: “The new name and tagline give Novo Holdings a more distinct profile and is in line with our strategy to become recognized as one of the world’s leading investors in life science, with a focus on longterm value creation.”
About Novo Holdings
Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation.
The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets.
In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets. Read more at www.novoholdings.dk
About the Novo Nordisk Foundation
The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. The Foundation has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social causes.
The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people. Since 2010, the Foundation has donated more than DKK 10 billion (€1.3 billion), primarily for research at public institutions and hospitals in Denmark and the other Nordic countries. Read more at www.novonordiskfoundation.com
Further information
Christian Mostrup Scheel, Senior Press Officer, cims@novo.dk, +45 3067 4805
Christian Mostrup Scheel
Senior Press Officer
Mobile: +45 3067 4810
cims@novo.dk
Novo Holdings A/S
Tuborg Havnevej 19
DK–2900 Hellerup
Denmark
novoholdings.dk
+45 3527 6500
CVR no 24 25 76 30
Record changed: 2023-06-05 |
Advertisement

More documents for Novo Group (Group)
- [1] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....
- [2] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
- [3] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
- [4] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....
- [5] AH Diagnostics A/S. (4/3/23). "Press Release: Helle Zacho Becomes the New CEO of the AH Diagnostics Group"....
- [6] Evosep ApS. (1/9/23). "Press Release: Evosep Receives Strategic Investment from Novo Holdings A/S to Accelerate Its Effort on Clinical Proteomics". Odense....
- [7] Novozymes A/S. (12/12/22). "Press Release: Novozymes and Chr. Hansen to Combine and Create a Leading Global Biosolutions Partner [Not for US, CA, et al.]". Copenhagen....
- [8] Novo Nordisk A/S. (11/22/22). "Press Release: Novo Nordisk Invests DKK 5.4 bn Danish Kroner in Expansion of Clinical Manufacturing Facilities in Bagsværd, Denmark". Bagsværd....
- [9] Inversago Pharma Inc.. (10/19/22). "Press Release: Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors". Montréal, QC....
- [10] Inversago Pharma Inc.. (10/17/22). "Press Release: Inversago Pharma Raises $95 Million CAD in Series C Financing". Montréal, QC....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top